MarketStar Founder Alan Hall Joins MediConnect Board of Directors

* Reuters is not responsible for the content in this press release.

Tue Apr 28, 2009 11:57am EDT

SALT LAKE CITY--(Business Wire)--
MediConnect Global, Inc. is pleased to announce Alan E. Hall as the newest
member of its Board of Directors. 

"We are honored to have Alan Hall join our Board of Directors," said CEO Amy
Rees Anderson. "Alan`s entrepreneurial experience and exceptional leadership
capabilities will be a tremendous asset to the company as we continue to lead
the charge of digitizing medical records across the globe." 

Hall is the founder and chairman of MarketStar Corporation, a global outsourced
marketing and sales company focused on assisting high-technology companies
increase sales in small to medium business sectors. 

MarketStar, owned by Omnicom Group (OMC), generates billions of dollars in sales
for its clientele. Hall is also the founder and chairman of Grow Utah Ventures,
a not-for-profit entity with a mission of stimulating economic development
through entrepreneurship. 

Recently, Hall established Mercato Partners, a growth equity venture capital
firm which invests in high-growth technology companies. Hall is the chairman of
the Utah Technology Council, a trustee of Weber State University, a member of
the Advisory Board of Wells Fargo Bank, and a trustee of the Intermountain
Healthcare Foundation. He has been the recipient of the Ernst & Young and
Mountain West Capital Network Entrepreneur of the Year awards. 

About MediConnect Global

MediConnect Global, Inc. is the leading medical records retrieval, scanning, and
storage services provider. MediConnect`s online RapidRetrieve system and
patented processes provide medical records over the internet in a secure and
efficient manner. It also provides global healthcare services. For more
information, please visit (http://www.mediconnect.net) or call (801) 545-3700. 





MediConnect Global Inc.
Elyse Peterson, 801-545-3717
epeterson@mediconnect.net

Copyright Business Wire 2009

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.